Inhibition of NF-κB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol)
© Grimm et al; licensee BioMed Central Ltd. 2006
Received: 05 November 2005
Accepted: 27 January 2006
Published: 27 January 2006
French maritime pine bark extract (Pycnogenol®) displays a variety of anti-inflammatory effects in vivo. Aim of this study was to determine whether human plasma after oral intake of Pycnogenol contains sufficient concentrations of active principles to inhibit key mediators of inflammation. Blood samples from seven healthy volunteers were obtained before and after five days administration of 200 mg Pycnogenol per day. Plasma samples statistically significantly inhibited matrix metalloproteinase 9 (MMP-9) release from human monocytes and NF-κB activation. Thus, we provide evidence that bioavailable active principles of Pycnogenol exert anti-inflammatory effects by inhibition of proinflammatory gene expression which is consistent with documented clinical observations. We suggest that our ex vivo method is suitable to substantiate molecular pharmacological mechanisms of complex plant extracts in a more focussed and rational way compared to in vitro studies by taking into account the processes of absorption and metabolism.
Pycnogenol is a standardized bark extract of the French maritime pine Pinus pinaster (Pycnogenol®, Horphag Research Ltd., UK). It comprises of a concentrate of pine bark constituents such as polyphenolic monomers, procyanidins and phenolic or cinnamic acids and their glycosides . About 65–75 % of the Pycnogenol extract are procyanidins that consist of catechin and epicatechin subunits of varying chain lengths . The quality of this extract is specified in the United States Pharmacopeia (USP 28) .
In human studies Pycnogenol revealed diverse anti-inflammatory actions . Double-blind, placebo-controlled studies in asthma patients showed reduced plasma  or urine  leukotriene concentrations after Pycnogenol supplementation, while asthma symptom scores and pulmonary function improved. Symptoms of osteoarthritis as pain and immobility of joints decreased in a double-blind, placebo-controlled study . Oral  and topical  application of Pycnogenol reduced inflammation and delayed skin-cancer formation following UV-radiation in controlled experiments in mice.
The anti-inflammatory mechanisms of maritime pine bark extract have been elucidated in a variety of in vitro and cell culture studies [8, 9]. Additionally to its radical scavenging activity an inhibition of NF-κB-dependent gene expression and decrease of the activity of various pro-inflammatory mediators and adhesion molecules was observed after incubation of cells with the Pycnogenol extract [8, 9]. This experimental in vitro design that pursues to uncover pharmacological effects by addition of plant extracts to cell cultures and subsequent measurement of cellular responses is widely employed. However, this methodology might inherit a couple of pitfalls.
Plant extracts often comprise of high molecular weight components that cannot be absorbed in the gastrointestinal tract and thus will never reach a target cell in vivo. Furthermore, there are examples of metabolites that are not present in the original extract, but are formed in vivo as a result of intestinal bacterial and/or hepatic metabolism. After ingestion of Pycnogenol, for example, two metabolites derived from catechin were detected in human urine, δ-(3,4-dihydroxy-phenyl)-γ-valerolactone and δ-(3-methoxy-4-hydroxy-phenyl)-γ-valerolactone . Valerolactone derivatives were also found after ingestion of green tea . These newly formed metabolites may display significant efficacy and contribute to the observed in vivo effects. We recently elucidated the cellular effects of δ-(3,4-dihydroxy-phenyl)-γ-valerolactone and δ-(3-methoxy-4-hydroxy-phenyl)-γ-valerolactone and uncovered an antioxidant activity as well as the potential to inhibit release and enzymatic activity of matrix metalloproteinase 9 (MMP-9) .
The purpose of the present study was to determine molecular pharmacological effects of maritime pine bark extract ex vivo after intake of regular doses by human volunteers. Therefore, we obtained plasma samples before and after five days administration of Pycnogenol to seven healthy humans. These plasma samples were analyzed in two different experimental settings to evaluate the influence of bioavailable actives principles on cellular key components that contribute to inflammatory processes. We investigated a potential influence of the plasma samples on LPS-induced release of MMP-9 from human monocytes. Since MMP-9 induction and release might be initiated by NF-κB activation we also determined the effect of the plasma samples on LPS-induced NF-κB nuclear translocation.
Seven healthy volunteers (five female and two male) aged 18 to 30 years participated in this study. The study was approved by the ethical committee of the Comenius University's Faculty of Medicine, Bratislava, Slovak Republic, and all participants gave written informed consent. After 24 hours of a diet free of flavonoids (no vegetables, fruits and fruit juices or marmalades, tea, coffee, cocoa, wine and beer) blood samples were drawn to obtain basal values. Subsequently, the volunteers took tablets containing 200 mg standardized maritime pine bark extract (Pycnogenol®, Horphag Research Ltd., UK) every morning for five days to reach steady state conditions of constituents and/or metabolites of Pycnogenol. Four hours after the last intake of Pycnogenol on day five a second blood sample was obtained from each volunteer. Again, a 24 hour period of a diet free of flavonoids preceded this blood sampling. Blood samples were centrifuged and plasma was aliquoted, shock frozen and stored at -80°C until further analysis.
Isolation and culture of human monocytes
Human monocytes were isolated from pooled blood cell suspensions (Bayerisches Rotes Kreuz, Wiesentheid, Germany) from different donors by Biocoll (Biochrom, Berlin, Germany) and subsequent Percoll (Pharmacia, Freiburg, Germany) density gradient centrifugation. Only blood cell suspensions of donors with blood type 0 were used for these experiments. The cells were first cultured overnight in Mc Coy's 5a modified medium (Biochrom, Berlin, Germany) supplemented with 15 % fetal calf plasma, 1 % penicilline/streptomycine, 1 % non-essential amino acids and 1 mM L-glutamine at a density of 5 × 106 cells/mL (NF-κB experiments) or 1 × 106 cells/mL (MMP-9 experiments) in a 6 % CO2 humidified atmosphere at 37°C (Hera cell incubator, Kendro Laboratory Products, Hanau, Germany). Cell experiments were performed in Multiwell™ 24-well cell culture plates, polystyrene, (BD Labware NJ, USA) with a final volume of 2.0 mL/well.
Inhibition of MMP-9 release from human monocytes
Plasma samples obtained before and after Pycnogenol intake were diluted 1:1 with RPMI medium (Biochrom, Berlin, Germany; supplemented with 1 % penicilline/streptomycine, 1 % non-essential amino acids and 1 mM L-glutamine) and incubated with monocytes for one hour. Cells were then stimulated with 10 ng/ml LPS (Lipopolysaccharides (rough strains) from Salmonella minnesota Re 595, Sigma-Aldrich Inc., Taufkirchen, Germany) and incubated at 37°C for 48 hours. The number of viable cells was determined by counting living cells after staining with trypane blue. Plates were centrifuged (Megafuge 1.0 R, Kendro Laboratory Products) and cell culture supernatants were harvested, diluted 1:25 and assayed for total MMP-9 protein concentrations by ELISA (Quantikine™ assay, R&D Systems, Minneapolis, USA) according to manufacturer's protocol.
Determination of NF-κB activation by ELISA
Plasma samples obtained before and after Pycnogenol intake were diluted 1:1 with RPMI medium as described above and incubated with monocytes overnight. Cells were then stimulated with 1 μg/mL LPS and incubated at 37°C for 60 minutes. After incubation the number of viable cells was determined by counting living cells after staining with trypane blue. Determination of free p65 in nuclear extracts was performed according to the manufacturer's protocol (ELISA-Kit NF-κB p65 ActivELISA™, Imgenex, CA, USA). The optical density of samples was determined using the microplate reader (Bio-Rad microplate reader, Benchmark CA, USA) set at 405 nm. Inhibitory effects of plasma constituents and metabolites after Pycnogenol intake were determined by comparing the p65 concentration of LPS-stimulated cells, incubated with plasma before and after Pycnogenol intake.
Statistical analysis (Wilcoxon matched pairs signed rank test) was performed using the GraphPad prism software (GraphPad Software Inc., San Diego CA, USA). Significance was defined as p < 0.05.
Human monocytes were incubated with diluted plasma samples (dilution 1:1 with cell culture medium) obtained from seven healthy volunteers before and after ingestion of maritime pine bark extract (Figure 1). The viability of monocytes was not significantly influenced by plasma samples obtained from Pycnogenol treated subjects. In the MMP-9 experiments the number of viable monocytes was 2.49 ± 0.23 × 105 after incubation with samples obtained before Pycnogenol intake and 2.79 ± 0.26 × 105 after incubation with plasma obtained after 5 days Pycnogenol ingestion. Likewise, no difference was observed in the number of viable cells in the NF-κB experiments. The number of viable monocytes was 1.49 ± 0.29 × 106 and 1.70 ± 0.20 × 106 after incubation with samples obtained before and after 5 days Pycnogenol intake.
Plant extracts may display a variety of interesting pharmacological effects in vivo. The bioefficacy of plant extracts is increasingly tested and documented in clinical intervention studies . While the efficacy of extracts is observed with increasing interest the elucidation of the molecular basis of biological or clinical effects remains a challenge. Usually plant extracts comprise of a complex mixture of various components and often enough it is not clear whether a single compound or a mixture of related compounds is responsible for the effects.
The standardized maritime pine bark extract Pycnogenol has documented clinical anti-inflammatory activities [1, 9]. In earlier studies we determined that the extract's metabolites δ-(3,4-dihydroxy-phenyl)-γ-valerolactone and δ-(3-methoxy-4-hydroxy-phenyl)-γ-valerolactone exhibited inhibitory activity on LPS-induced secretion of matrix metalloproteinase 9 (MMP-9) from human monocytes . However, so far it remained elusive whether sufficiently high in vivo concentrations of any active extract components would be achieved after peroral intake of Pycnogenol. In the present study we applied an ex vivo methodology that takes absorption and metabolism of the extract into account. The plasma samples obtained from volunteers after ingestion of Pycnogenol were expected to contain active extract components that should attenuate inflammatory processes.
Indeed, we observed a statistically significant mean decrease of about 25 % in MMP-9 release when LPS-activated human monocytes were exposed to plasma of volunteers after repeated intake of Pycnogenol. The matrix degrading enzyme MMP-9 is highly expressed at sites of inflammation and contributes to the pathogenesis of various chronic inflammatory diseases. In asthma MMP-9 is upregulated and involved in remodeling processes [18–20]. MMP-9 also facilitates recruitment of inflammatory cells such as eosinophils and neutrophils across basement membranes . Expression of MMP-9 was negatively correlated with pulmonary function in asthmatic patients . As Pycnogenol has been reported to attenuate signs of inflammation in asthma patients [3, 4] we now provide first evidence that this anti-inflammatory in vivo effect might be at least partially attributed to reduced MMP-9 secretion on a molecular level.
NF-κB is a molecule with a master function in inflammatory cytokine induction. It is also involved in regulation of immune functions, cell cycle control and apoptosis . Upon nuclear translocation in response to an inflammatory stimulus it regulates various genes coding for proinflammatory mediators. We found that plasma of Pycnogenol treated volunteers statistically significantly inhibited NF-κB activation in LPS-stimulated monocytes by about 15 %. Though this effect is rather moderate it might well contribute to the anti-inflammatory effects of Pycnogenol in patients. Interestingly, NF-κB is also involved in MMP-9 expression [22, 23]. Consistent with these reports we observed a positive correlation between inhibitory activity of matched plasma samples on MMP-9 and NF-κB. In vitro inhibition of NF-κB activation by plant extracts or constituents has been reported repeatedly . Blocking IκB kinase activity has been reported as the underlying mechanism for restricting NF-κB activation by green tea polyphenols . The mechanism of ex vivo inhibition of NF-κB nuclear translocation by plasma containing bioavailable active principles after Pycnogenol ingestion has yet to be identified.
To summarize, regular doses of perorally administered French maritime pine bark extract moderately inhibited NF-κB activation and MMP-9 secretion ex vivo. Since the plasma samples of the volunteers were diluted 1:1 with cell culture medium before incubation with the monocytes it can be assumed that in vivo effects might be even more pronounced. The observed ex vivo effects with plasma of volunteers after Pycnogenol intake are consistent with reported clinical anti-inflammatory effects in vivo. The next challenge will be to identify the responsible active principle(s) in the plasma samples. After all, however, the suggested methodology is a rational and focussed technique to explain biological effects from in vivo studies on a molecular pharmacological basis. The next target will be to link pharmacodynamic data with pharmacokinetics and to identify the active component(s) in plasma samples.
- Rohdewald P: A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther. 2002, 40: 158-168.PubMedView ArticleGoogle Scholar
- Maritime Pine Extract. United States Pharmacopeia. 2005, Rockville, United States Pharmacopeial Convention, Inc., 28: 2115-2116.
- Hosseini S, Pishnamazi S, Sadrzadeh SM, Farid F, Farid R, Watson RR: Pycnogenol((R)) in the Management of Asthma. J Med Food. 2001, 4: 201-209. 10.1089/10966200152744472.PubMedView ArticleGoogle Scholar
- Lau BH, Riesen SK, Truong KP, Lau EW, Rohdewald P, Barreta RA: Pycnogenol as an adjunct in the management of childhood asthma. J Asthma. 2004, 41: 825-832. 10.1081/JAS-200038433.PubMedView ArticleGoogle Scholar
- Farid R, Mirteizi A, Mirheidari M, Rezaieyazdi S, Mansouritorghabeh H, Zibadi S, Watson RR: Pycnogenol® reduces clinical symptoms of knee osteoarthritis. Arthritis Care Res. accepted for publication
- Kyriazi M, Yova D, Rallis M, Lima A: Cancer chemopreventive effects of Pinus Maritima bark extract on ultraviolet radiation and ultraviolet radiation-7,12,dimethylbenz(a)anthracene induced skin carcinogenesis of hairless mice. Cancer Lett. 2005Google Scholar
- Sime S, Reeve VE: Protection from inflammation, immunosuppression and carcinogenesis induced by UV radiation in mice by topical Pycnogenol. Photochem Photobiol. 2004, 79: 193-198. 10.1562/0031-8655(2004)079<0193:PFIIAC>2.0.CO;2.PubMedView ArticleGoogle Scholar
- Packer L, Rimbach G, Virgili F: Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radic Biol Med. 1999, 27: 704-724. 10.1016/S0891-5849(99)00090-8.PubMedView ArticleGoogle Scholar
- Rohdewald PJ: Pycnogenol , French Maritime Pine Bark Extract. Encyclopedia of Dietary Supplements. 2005, New York, Marcel Dekker, 545-553.Google Scholar
- Düweler KG, Rohdewald P: Urinary metabolites of French maritime pine bark extract in humans. Pharmazie. 2000, 55: 364-368.PubMedGoogle Scholar
- Meng X, Sang S, Zhu N, Lu H, Sheng S, Lee MJ, Ho CT, Yang CS: Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats. Chem Res Toxicol. 2002, 15: 1042-1050. 10.1021/tx010184a.PubMedView ArticleGoogle Scholar
- Grimm T, Schäfer A, Högger P: Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Free Radic Biol Med. 2004, 36: 811-822. 10.1016/j.freeradbiomed.2003.12.017.PubMedView ArticleGoogle Scholar
- Teucher T, Obertreis B, Ruttkowski T, Schmitz H: [Cytokine secretion in whole blood of healthy subjects following oral administration of Urtica dioica L. plant extract]. Arzneimittelforschung. 1996, 46: 906-910.PubMedGoogle Scholar
- Wagner I, Greim C, Laufer S, Heide L, Gleiter CH: Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor alpha or interleukin 1 beta release in vitro and ex vivo. Clin Pharmacol Ther. 2003, 73: 272-274. 10.1067/mcp.2003.32.PubMedView ArticleGoogle Scholar
- Loew D, Mollerfeld J, Schrodter A, Puttkammer S, Kaszkin M: Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. Clin Pharmacol Ther. 2001, 69: 356-364. 10.1067/mcp.2001.115445.PubMedView ArticleGoogle Scholar
- Notka F, Meier G, Wagner R: Concerted inhibitory activities of Phyllanthus amarus on HIV replication in vitro and ex vivo. Antiviral Res. 2004, 64: 93-102. 10.1016/j.antiviral.2004.06.010.PubMedGoogle Scholar
- Williamson G, Manach C: Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr. 2005, 81: 243S-255S.PubMedGoogle Scholar
- Lee YC, Lee HB, Rhee YK, Song CH: The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma. Clin Exp Allergy. 2001, 31: 1623-1630. 10.1046/j.1365-2222.2001.01211.x.PubMedView ArticleGoogle Scholar
- Kelly EA, Jarjour NN: Role of matrix metalloproteinases in asthma. Curr Opin Pulm Med. 2003, 9: 28-33. 10.1097/00063198-200301000-00005.PubMedView ArticleGoogle Scholar
- Wenzel SE, Balzar S, Cundall M, Chu HW: Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol. 2003, 111: 1345-1352. 10.1067/mai.2003.1464.PubMedView ArticleGoogle Scholar
- Celec P: Nuclear factor kappa B--molecular biomedicine: the next generation. Biomed Pharmacother. 2004, 58: 365-371. 10.1016/j.biopha.2003.12.015.PubMedView ArticleGoogle Scholar
- Chung TW, Moon SK, Chang YC, Ko JH, Lee YC, Cho G, Kim SH, Kim JG, Kim CH: Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism. Faseb J. 2004, 18: 1670-1681. 10.1096/fj.04-2126com.PubMedView ArticleGoogle Scholar
- Ho TY, Bagnell CA: Relaxin Induces Matrix Metalloproteinase-9 through Activation of Nuclear Factor Kappa B in Human THP-1 Cells. Ann N Y Acad Sci. 2005, 1041: 314-316. 10.1196/annals.1282.049.PubMedView ArticleGoogle Scholar
- Kim HP, Son KH, Chang HW, Kang SS: Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci. 2004, 96: 229-245. 10.1254/jphs.CRJ04003X.PubMedView ArticleGoogle Scholar
- D'Acquisto F, May MJ, Ghosh S: Inhibition of Nuclear Factor Kappa B (NF-B): An Emerging Theme in Anti-Inflammatory Therapies. Mol Interv. 2002, 2: 22-35. 10.1124/mi.2.1.22.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.